THERAPEUTIC EFFECTS OF LIVIDOMYCIN IN THE RETREATMENT FOR PULMONARY TUBERCULOSIS PATIENTS

Abstract

The therapeutic effects of Lividomycin (LVM) in the retreatment for advancedpulmonary tuberculosis patients were observed.
The patients subjected to this study were 41 cases as listed in table 1, and thebackground factors of these cases were as follows: as for age, younger than 39 years of agein 14 cases, between 40 and 59 years in 23, and older than 60 years in 4; as for the extentof disease by N. T. A. classification, minimal in 1, moderately advanced in 11, far advancedin 29; and as for the cavity, no cavity in 1 case, with non-sclerotic walled cavity in 8 andwith sclerotic walled cavity in 31 cases.
LVM was administered twice a week, and the daily dose of LVM was 2gm. for thepatients with body weight 50kg or more, and 1.5gm. for the patients less than 50kg. In 15 cases, other susceptible or previously unused drug was combined with LVM, while in 26 cases no such drug was combined.
The rate of sputum conversion 3 months after administration of LVM was 53.4% and54.2% after 6 months in the cases other susceptible or previously unused drugs werecombined, and 26.1% and 31.8%, respectively, in the cases no other susceptible orpreviously unused drugs were combined (table 2).
In 21 cases, the susceptibility of bacilli to LVM and KM before the treatment of LVMwas measured. In 7 cases, the bacilli were not susceptible to KM, while in 4 of them thebacilli were susceptible to LVM, and in the other 3 the susceptibility of the bacilli to LVM were slightly decreased. In other 14 cases, the bacilli were susceptible to both LVM andKM (table 3).
In 4 cases, the susceptibility of bacilli to LVM were decreased in the course of LVMtreatment and those to KM were also decreased simultaneously in all cases (table 4).
The adverse effects of LVM were listed in table 5, and the hearing ability at 8, 000c/s inaudiogram was disturbed in 26.3% of the cases during 6 months administration of LVM.